Telmisartan and cardioprotection

References

• Lloyd-JonesDAdamsRJBrownTMHeart disease and stroke statistics – 2010 update: a report from the American Heart AssociationCirculation20101217e46e21520019324
   PubMed Web of Science ®Google Scholar
• McFarlaneSIKumarASowersJRMechanisms by which angiotensin- converting enzyme inhibitors prevent diabetes and cardiovascular diseaseAm J Cardiol20039112A30H37H
   PubMedGoogle Scholar
• DanchinNCucheratMThuillezCDurandEKadriZStegPGAngiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trialsArch Intern Med2006166778779616606817
   PubMedGoogle Scholar
• ZouZXiGLYuanHBZhuQFShiXYTelmisartan versus angiotension- converting enzyme inhibitors in the treatment of hypertension: a meta-analysis of randomized controlled trialsJ Hum Hypertens200923533934918987649
   PubMed Web of Science ®Google Scholar
• XiGLChengJWLuGCMeta-analysis of randomized controlled trials comparing telmisartan with losartan in the treatment of patients with hypertensionAm J Hypertens200821554655218437146
   PubMed Web of Science ®Google Scholar
• WilliamsBLacourciereYSchumacherHGossePNeutelJMAntihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trialsJ Hum Hypertens200923961061919225530
   PubMed Web of Science ®Google Scholar
• GersteinHCMannJFYiQAlbuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individualsJAMA2001286442142611466120
   PubMed Web of Science ®Google Scholar
• BarnettAHBainSCBouterPAngiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathyN Engl J Med2004351191952196115516696
   PubMed Web of Science ®Google Scholar
• MakinoHHanedaMBabazonoTPrevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetesDiabetes Care20073061577157817389334
   PubMed Web of Science ®Google Scholar
• GalleJSchwedhelmEPinnettiSBogerRHWannerCAntiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathyNephrol Dial Transplant200823103174318318450829
   PubMed Web of Science ®Google Scholar
• BakrisGBurgessEWeirMDavidaiGKovalSTelmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathyKidney Int200874336436918496508
   PubMed Web of Science ®Google Scholar
• GrangerCBMcMurrayJJYusufSEffects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trialLancet2003362938677277613678870
   PubMed Web of Science ®Google Scholar
• DahlofBDevereuxRBKjeldsenSECardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenololLancet20023599311995100311937178
   PubMed Web of Science ®Google Scholar
• McMurrayJJOstergrenJSwedbergKEffects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trialLancet2003362938676777113678869
   PubMed Web of Science ®Google Scholar
• YusufSTeoKKPogueJTelmisartan, ramipril, or both in patients at high risk for vascular eventsN Engl J Med2008358151547155918378520
   PubMed Web of Science ®Google Scholar
• YusufSTeoKAndersonCEffects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trialLancet200837296441174118318757085
   PubMed Web of Science ®Google Scholar
• YusufSDienerHCSaccoRLTelmisartan to prevent recurrent stroke and cardiovascular eventsN Engl J Med2008359121225123718753639
   PubMed Web of Science ®Google Scholar
• McMurrayJJHolmanRRHaffnerSMEffect of valsartan on the incidence of diabetes and cardiovascular eventsN Engl J Med2010362161477149020228403
   PubMed Web of Science ®Google Scholar
• VerdecchiaPSleightPManciaGEffects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular DiseaseCirculation2009120141380138919770395
   PubMed Web of Science ®Google Scholar
• SchneiderMPHuaTABohmMWachtellKKjeldsenSESchmiederREPrevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysisJ Am Coll Cardiol201055212299230720488299
   PubMed Web of Science ®Google Scholar
• YusufSGersteinHHoogwerfBRamipril and the development of diabetesJAMA2001286151882188511597291
   PubMed Web of Science ®Google Scholar
• BoschJYusufSGersteinHCEffect of ramipril on the incidence of diabetesN Engl J Med2006355151551156216980380
   PubMed Web of Science ®Google Scholar
• McCallKLCraddockDEdwardsKEffect of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on the rate of new-onset diabetes mellitus: a review and pooled analysisPharmacotherapy20062691297130616945052
   PubMed Web of Science ®Google Scholar
• SchuppMJankeJClasenRUngerTKintscherUAngiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activityCirculation2004109172054205715117841
   PubMed Web of Science ®Google Scholar
• BensonSCPershadsinghHAHoCIIdentification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma- modulating activityHypertension2004435993100215007034
   PubMed Web of Science ®Google Scholar
• SchuppMClemenzMGinesteRMolecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activityDiabetes200554123442345216306360
   PubMed Web of Science ®Google Scholar
• FujisakaSUsuiIKanataniYTelmisartan improves insulin resistance and modulates adipose tissue macrophage polarization in high-fat-fed miceEndocrinology201115251789179921427223
   PubMed Web of Science ®Google Scholar
• WatanabeMInukaiKSumitaTEffects of telmisartan on insulin resistance in Japanese type 2 diabetic patientsIntern Med201049171843184720823643
   PubMed Web of Science ®Google Scholar
• MarketouMEKontarakiJETsakountakisNADifferential effect of telmisartan and amlodipine on monocyte chemoattractant protein-1 and peroxisome proliferator-activated receptor-gamma gene expression in peripheral monocytes in patients with essential hypertensionAm J Cardiol20111071596321146687
   PubMed Web of Science ®Google Scholar